These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37719841)

  • 1. Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.
    Huang Y; You M; Wu Q; Chen R
    Front Pharmacol; 2023; 14():1238009. PubMed ID: 37719841
    [No Abstract]   [Full Text] [Related]  

  • 2. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
    Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
    Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
    Lai S; Luo S; Huang Q; Lin S; Huang X; Xue H; Cai Y; Xu X; Weng X
    Pharmacogenomics; 2024; 25(5-6):249-257. PubMed ID: 38884946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
    Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
    Shitara K; Shah MA; Lordick F; Bang YJ; Ilson D; Van Cutsem E; Enzinger P; Kim SS; Klempner SJ; Moran D; Park JW; Bhattacharya P; Ajani JA; Xu RH
    Future Oncol; 2024; 20(26):1861-1877. PubMed ID: 38861294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
    Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
    Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.
    Lordick F; Van Cutsem E; Shitara K; Xu RH; Ajani JA; Shah MA; Oh M; Ganguli A; Chang L; Rhoten S; Bhattacharya P; Matsangou M; Park JW; Pophale R; Ranganath R; Kang YK
    ESMO Open; 2024 Aug; 9(8):103663. PubMed ID: 39146670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zolbetuximab: First Approval.
    Keam SJ
    Drugs; 2024 Aug; 84(8):977-983. PubMed ID: 38967717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis.
    Zhang PF; Shi XQ; Li Q
    Cost Eff Resour Alloc; 2023 Sep; 21(1):65. PubMed ID: 37705023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
    Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
    Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer.
    You M; Zeng X; Zhang J; Huang Y; Zhang Y; Cai Z; Hu Y
    Front Immunol; 2023; 14():1267322. PubMed ID: 37731489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.
    Shu Y; Ding Y; Zhang Q
    Front Oncol; 2022; 12():851522. PubMed ID: 35515123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial.
    You M; Zheng Q; He Y
    Front Pharmacol; 2024; 15():1412292. PubMed ID: 39391700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Xu RH; Ajani JA; Moran D; Guerrero A; Li R; Pavese J; Matsangou M; Bhattacharya P; Ueno Y; Wang X; Shah MA
    Gastric Cancer; 2024 Sep; 27(5):1058-1068. PubMed ID: 38954176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context.
    Wu B; Ye M; Chen H; Shen JF
    Clin Ther; 2012 Feb; 34(2):468-79. PubMed ID: 22325735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
    de Moraes FCA; Pasqualotto E; Chavez MP; Ferreira ROM; De Castria TB; Burbano RMR
    BMC Cancer; 2024 Feb; 24(1):240. PubMed ID: 38383390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yang J; Han J; Tian M; Tian K; Liao W; Yan X
    Cancer Manag Res; 2020; 12():12905-12913. PubMed ID: 33364838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.
    Lu T; Huang Y; Cai Z; Lin W; Chen X; Chen R; Hu Y
    Front Pharmacol; 2023; 14():1171302. PubMed ID: 37564176
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
    Jiang Y; Li Y; Wang LXW
    Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.